Roche Holding AG Shares Outstanding 2012-2025 | RHHBY
Roche Holding AG shares outstanding history from 2012 to 2025. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
- Roche Holding AG shares outstanding for the quarter ending December 31, 2025 were 0M, a 0% increase year-over-year.
- Roche Holding AG 2025 shares outstanding were 6.424B, a 0.12% increase from 2024.
- Roche Holding AG 2024 shares outstanding were 6.416B, a 0.25% decline from 2023.
- Roche Holding AG 2023 shares outstanding were 6.432B, a 0.5% decline from 2022.
|
Roche Holding AG Annual Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2025 | 6,424 |
| 2024 | 6,416 |
| 2023 | 6,432 |
| 2022 | 6,464 |
| 2021 | 6,880 |
| 2020 | 6,920 |
| 2019 | 6,912 |
| 2018 | 6,880 |
| 2017 | 6,880 |
| 2016 | 6,880 |
| 2015 | 6,897 |
| 2014 | 6,906 |
| 2013 | 13,808 |
| 2012 | 13,676 |
| 2011 | 6,807 |
|
Roche Holding AG Quarterly Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2025-12-31 | |
| 2025-06-30 | |
| 2024-12-31 | |
| 2024-06-30 | |
| 2023-12-31 | |
| 2023-06-30 | |
| 2022-12-31 | |
| 2022-06-30 | |
| 2021-12-31 | |
| 2021-06-30 | |
| 2020-12-31 | |
| 2020-06-30 | |
| 2019-12-31 | |
| 2019-06-30 | |
| 2018-12-31 | |
| 2018-06-30 | |
| 2017-12-31 | |
| 2017-06-30 | |
| 2016-12-31 | |
| 2016-06-30 | |
| 2015-12-31 | |
| 2015-06-30 | |
| 2014-12-31 | |
| 2014-06-30 | |
| 2013-12-31 | |
| 2013-06-30 | |
| 2012-12-31 | |
| 2012-06-30 | |
| 2011-12-31 | |
| 2011-06-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $318.782B | $76.450B |
| Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |